Shares of Biogen were falling this week after the U.S. Medicare program’s proposal to severely limit coverage of new Alzheimer’s treatments included Biogen’s Aduhelm. This may threaten to hurt the company’s sales of the controversial drug. Aduhelm, given as a monthly infusion, is a monoclonal antibody designed to remove a type of brain plaque associated … Continue reading “Biogen Shares Fall as Medicare Proposal Restricts Alzheimer’s Treatment Coverage”
